The Mitochondria are the powerhouses of every cell. This is something that we all learned a long time ago in 8th grade biology. However, the story of the role of the mitochondria goes much deeper than just providing power. We know now that the mitochondria may be the cause of a legion of diseases when…(Read More)
Blue Bell, Pennsylvania—is delighted to announced that it was awarded Orphan Drug Designation by FDA for its mitochondrial targeted compound, MP-101 for treating Amyotrophic Lateral Sclerosis (ALS). This important allowance, along with the Company’s open IND will help secure the path forward for the continued clinical development of MP-101 in ALS…(Read More)
Blue Bell, Pennsylvania (BUSINESS WIRE) — Mitochon Pharmaceuticals today announced that they, in partnership with the University of Kentucky (UK) and Children’s Hospital of Philadelphia (CHOP), were awarded a $3.2M National Institutes of Health grant to study Mitochon’s mitochondrial targeted drug therapies for treating Traumatic Brain Injury (TBI). This important award, along with…(Read More)
Traumatic brain injury (TBI) results in cognitive impairment, which can be long-lasting after moderate to severe TBI. Currently, there are no FDA-approved therapeutics to treat the devastating consequences of TBI and…(Read More)
Dopaminergic neuronal cell loss in the substantia nigra is responsible for the motor symptoms that are the clinical hallmark of Parkinson’s disease (PD). As of yet there are no treatments that slow or prevent the degeneration of…(Read More)
Mitochondrial dysfunction is thought to be involved in the pathogenesis of MS and here we tested if brain penetrant mitochondrial uncouplers, DNP (MP101) and a novel prodrug of DNP (MP201), have the pharmacology to suppress demyelination and axonal loss in two independent models of MS by modulating the entire…(Read More)
By Erica Slaughter Huntington disease (HD), a genetically dominant trinucleotide repeat disorder resulting from cytosine-adenine-guanine (CAG) repeats within the huntingtin (HTT) gene, has a near-full pene- trance and onset of symptomatology and neuronal loss typically by the third decade of life. A neuropathological hallmark of HD is cortical atrophy, as indicated in…(Read More)
In the sanctity of pure drug discovery, objective reasoning can become clouded when pursuing ideas that appear unorthodox, but are spot on physiologically. To put this into historical perspective, it was an unorthodox idea in the 1950’s to suggest that warfarin, a rat poison, could be repositioned into a breakthrough drug in humans…(Read More)
Blue Bell, Pennsylvania (BUSINESS WIRE) — Mitochon Pharmaceuticals today announced that it was awarded Orphan Drug Designation by FDA for its mitochondrial targeted compound, MP-101 for treating Huntington’s Disease. This important allowance, along with the Company’s open IND will help secure the path forward for the continued clinical development of MP101 in Huntington…(Read More)
Disease Modifying Therapies for Neurodegenerative Diseases…(Read More)